骨科医生重视骨质疏松性骨折的治疗及预防吗?

被引:15
作者
贺良 [1 ]
钟伟 [2 ]
李宁 [1 ]
机构
[1] 北京积水潭医院创伤骨科
[2] 潍坊医学院外科学教研室
关键词
骨质疏松; 骨折; 骨科; 医生;
D O I
10.13795/j.cnki.sgkz.2009.04.002
中图分类号
R580 []; R683 [骨折、骨的损伤];
学科分类号
100220 [骨科学];
摘要
目的调查骨科医生掌握骨质疏松症的相关知识,以及在处理骨质疏松性骨折患者时对患者骨质疏松症进行药物治疗的情况,以此促进医生重视对骨质疏松性骨折的治疗及预防。方法通过调查问卷的方式对北京市、东北地区、山东省、河北省、河南省等地一些~级医院的骨科医生进行调查,内容包括骨质疏松症相关知识,骨质疏松性骨折患者的骨质疏松症治疗状况等。结果在诊断方面,70.1%的医生认为,对骨质疏松症进行药物治疗之前应该先进行骨密度测定以确定诊断。53.5%的医生认为,患者的骨质疏松性骨折及他们所具有的骨质疏松危险因素(如吸烟、大量饮酒、绝经后女性等)是患有骨质疏松症的确切证据,应该进行药物治疗。38.6%的医生认为,在推荐患者对骨质疏松症进一步治疗前,应该对患者进行健康检查以确定患者是否有引起骨质疏松的其他原因。在治疗方面,74.8%的骨科医生认为,对骨质疏松性骨折患者的骨质疏松症应该进行药物治疗。在选择药物方面,赞成对骨质疏松症进行药物治疗的医生中,40.9%建议应用双磷酸盐,约45%的医生倾向于使用维生素D及钙剂。事实上,75.5%的骨科医生因为考虑到其他问题而没有对骨质疏松症进行药物治疗。结论尽管大多数的骨科医生都认为应该对骨质疏松性骨折患者进行除骨折以外的骨质疏松症治疗,但是还有相当多的医生并没有对患者进行骨质疏松症的药物治疗,他们认为由骨质疏松专科医生进行药物治疗更为妥善。
引用
收藏
页码:241 / 244
页数:4
相关论文
共 10 条
[1]
Barriers to effective management of osteoporosis in moderate and minimal trauma fractures: a prospective study [J].
Bliuc, D ;
Ong, CR ;
Eisman, JA ;
Center, JR .
OSTEOPOROSIS INTERNATIONAL, 2005, 16 (08) :977-982
[2]
A meta-analysis of previous fracture and subsequent fracture risk [J].
Kanis, JA ;
Johnell, O ;
De Laet, C ;
Johansson, H ;
Oden, A ;
Delmas, P ;
Eisman, J ;
Fujiwara, S ;
Garnero, P ;
Kroger, H ;
McCloskey, EV ;
Mellstrom, D ;
Melton, LJ ;
Pols, H ;
Reeve, J ;
Silman, A ;
Tenenhouse, A .
BONE, 2004, 35 (02) :375-382
[3]
Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate [J].
Watts, NB ;
Cooper, C ;
Lindsay, R ;
Eastell, R ;
Manhart, MD ;
Barton, IP ;
van Staa, TP ;
Adachi, JD .
JOURNAL OF CLINICAL DENSITOMETRY, 2004, 7 (03) :255-261
[4]
Multinational survey of osteoporotic fracture management.[J]..Osteoporosis International.2005, 2
[5]
Practice patterns in the diagnosis and treatment of osteoporosis after a fragility fracture: a systematic review [J].
Elliot-Gibson, V ;
Bogoch, ER ;
Jamal, SA ;
Beaton, DE .
OSTEOPOROSIS INTERNATIONAL, 2004, 15 (10) :767-778
[6]
The fracture liaison service: success of a program for the evaluation and management of patients with osteoporotic fracture [J].
McLellan, AR ;
Gallacher, SJ ;
Fraser, M ;
McQuillian, C .
OSTEOPOROSIS INTERNATIONAL, 2003, 14 (12) :1028-1034
[7]
Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis [J].
Harrington, JT ;
Ste-Marie, LG ;
Brandi, ML ;
Civitelli, R ;
Fardellone, P ;
Grauer, A ;
Barton, I ;
Boonen, S .
CALCIFIED TISSUE INTERNATIONAL, 2004, 74 (02) :129-135
[8]
Analysis of 1-year vertebral fracture risk reduction data in treatments for osteoporosis [J].
Miller, P .
SOUTHERN MEDICAL JOURNAL, 2003, 96 (05) :478-485
[9]
Barriers to osteoporosis identification and treatment among primary care physicians and orthopedic surgeons [J].
Simonelli, C ;
Killeen, K ;
Mehle, S ;
Swanson, L .
MAYO CLINIC PROCEEDINGS, 2002, 77 (04) :334-338
[10]
Interim report and recommendations of the World Health Organization task-force for osteoporosis [J].
Genant, HK ;
Cooper, C ;
Poor, G ;
Reid, I ;
Ehrlich, G ;
Kanis, J ;
Nordin, BEC ;
Barrett-Connor, E ;
Black, D ;
Bonjour, JP ;
Dawson-Hughes, B ;
Delmas, PD ;
Dequeker, J ;
Eis, SR ;
Gennari, C ;
Johnell, O ;
Johnston, CC ;
Lau, EMC ;
Liberman, UA ;
Lindsay, R ;
Martin, TJ ;
Masri, B ;
Mautalen, CA ;
Meunier, PJ ;
Miller, PD ;
Mithal, A ;
Morii, H ;
Papapoulos, S ;
Woolf, A ;
Yu, W ;
Khaltaev, N .
OSTEOPOROSIS INTERNATIONAL, 1999, 10 (04) :259-264